Pharmaceutical

Bavarian Nordic shares sink by 12% after mpox sales slump in Q3

Revenue for the mpox vaccine is down compared to last year however its travel vaccine business grew by 21%.

Nov 17, 2024 - 06:00
Bavarian Nordic shares sink by 12% after mpox sales slump in Q3
Revenue for the mpox vaccine is down compared to last year however its travel vaccine business grew by 21%.
Read the original article

Tags:

Previous Article

FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio

Rystiggo receives FDA approval, strengthening UCB’s mya...

Jun 27, 2023

Opinion: In a world of synthetic biology, publishing virus DNA sequences may mean perishing

Opinion: In a world of synthetic biology, publishing vi...

Apr 7, 2023

STAT+: What to know about concerns raised by compounded versions of Novo Nordisk’s Wegovy

STAT+: What to know about concerns raised by compounded...

Aug 11, 2023